Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Leerink Partners and Cantor are acting as joint book-running managers for the offering. Eledon currently intends to use the net proceeds from the proposed offering to support the continued clinical ...

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering. Oppenheimer & Co., Truist Securities and LifeSci Capital are acting as ...

Why cutting drug prices is pushing Eli Lilly's stock toward an all-time high

The company's shares (LLY) climbed 2.5% in afternoon trading on Tuesday, after closing at a record high of $966.64 on Monday. That rally pushed Lilly's market capitalization up to $937 billion, ...
BioSpace

Cogent Hits ‘Unprecedented’ Efficacy in Rare Stomach Cancer, Clearing Path to FDA

Cogent Biosciences expects to file a new drug application for bezuclastinib in gastrointestinal stromal tumors early next ...
Fintel on MSN

Leerink Partners Maintains uniQure N.V. (QURE) Outperform Recommendation

Fintel reports that on November 10, 2025, Leerink Partners maintained coverage of uniQure N.V. (NasdaqGS:QURE) with a ...
newscase

Eli Lilly Stock: Major Expansion Initiatives Fuel Growth Outlook

Eli Lilly and Company is positioned for substantial growth following significant regulatory and strategic developments.
Fintel on MSN

Leerink Partners Maintains Cogent Biosciences (COGT) Outperform Recommendation

Fintel reports that on November 10, 2025, Leerink Partners maintained coverage of Cogent Biosciences (NasdaqGS:COGT) with a ...

Eli Lilly Stock Surges As Analyst Sees More Room To Run

Eli Lilly shares are rising Monday after Leerink Partners upgraded the stock to Outperform and raised its price target to ...
Fierce Biotech

Merck's PCSK9 pill holds 'significant advantage' with injectable-like cholesterol reductions: analysts

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...

Roche's experimental MS drug hits main goal in one of two key trials

Roche's experimental multiple sclerosis drug achieved its main goal in one of two key late-stage trials testing it against ...

Pfizer wins $10 billion bidding war for obesity drug developer

Metsera accepted a sweetened offer from Pfizer late on Friday, citing U.S. antitrust risks in Novo’s bid that it had ...

Evommune Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

The gross proceeds to Evommune from the initial public offering before deducting underwriting discounts and commissions and offering expenses were $172.5 million. The shares began trading on the New ...